JAK2 Gene - Janus Kinase 2

📖 Wiki Page

gene1749 wordssynced 2026-04-02

JAK2 Gene - Janus Kinase 2

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">JAK2 Gene - Janus Kinase 2</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Ruxolitinib</td>
<td>JAK1/JAK2</td>
</tr>
<tr>
<td class="label">Tofacitinib</td>
<td>JAK1/JAK2/JAK3</td>
</tr>
<tr>
<td class="label">Baricitinib</td>
<td>JAK1/JAK2</td>
</tr>
<tr>
<td class="label">Upadacitinib</td>
<td>JAK1</td>
</tr>
<tr>
<td class="label">Fedratinib</td>
<td>JAK2</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">IL-6R/gp130</td>
<td>Receptor binding</td>
</tr>
<tr>
<td class="label">EPO-R</td>
<td>Receptor binding</td>
</tr>
<tr>
<td class="label">STAT3</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">STAT5</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">PIAS3</td>
<td>Protein binding</td>
</tr>
<tr>
<td class="label">SOCS3</td>
<td>Protein binding</td>
</tr>
<tr>
<td class="label">PTP1B</td>
<td>Dephosphorylation</td>
</tr>
<tr>
<td class="label">Grb2</td>
<td>SH3 binding</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Specificity</td>
</tr>
<tr>
<td class="label">Ruxolitinib</td>
<td>JAK1/JAK2</td>
</tr>
<tr>
<td class="label">Tofacitinib</td>
<td>JAK1/JAK2/JAK3</td>
</tr>
<tr>
<td class="label">Baricitinib</td>
<t

...

JAK2 Gene - Janus Kinase 2

Overview

Jak2 Gene Janus Kinase 2 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Pathway Diagram

Mermaid diagram (expand to render)

Introduction

Janus Kinase 2 (JAK2) is a critical non-receptor tyrosine kinase that mediates cytokine receptor signaling and plays essential roles in immune regulation, hematopoiesis, and cellular stress responses. The JAK2 gene, located on chromosome 9p24.1, encodes a 1132-amino acid protein (~130 kDa) belonging to the Janus kinase family (JAK1, JAK2, JAK3, TYK2). JAK2 transduces signals from various cytokine receptors, including those for interleukin-6 (IL-6), interferons (IFN-α/β/γ), erythropoietin (EPO), thrombopoietin (TPO), and granulocyte colony-stimulating factor (G-CSF), primarily through the JAK-STAT (Signal Transducer and Activator of Transcription) signaling pathway. [@liu2018]

In the central nervous system, JAK2 is expressed in neurons, astrocytes, [microglia](/cell-types/microglia-neuroinflammation), and oligodendrocytes, where it participates in neuroinflammation, synaptic plasticity, and neuronal survival. Dysregulated JAK2 signaling has been implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), and multiple sclerosis (MS). The JAK-STAT pathway's role in microglial activation and neuroinflammation makes JAK2 an attractive therapeutic target for neurodegenerative diseases. [@qin2020]

Gene and Protein Structure

The JAK2 gene spans approximately 16 kb on chromosome 9p24.1 and consists of 23 coding exons. The resulting protein contains 1132 amino acids with a molecular weight of ~130 kDa. [@nicolas2013]

Domain Architecture

FERM Domain (JH7-JH5, ~400 aa): Located at the N-terminus, this domain is essential for association with cytokine receptors. The FERM domain directly contacts the membrane-proximal region of cytokine receptor subunits.
SH2-Like Domain (JH4-JH3): Functions as a regulatory domain that participates in protein-protein interactions and subcellular localization.
Pseudokinase Domain (JH2, ~300 aa): This domain shares kinase fold homology but lacks catalytic activity. The JH2 domain maintains JAK2 in an inactive conformation through intramolecular interactions. Mutations in this domain (e.g., V617F) cause constitutive activation.
Kinase Domain (JH1, ~300 aa): The C-terminal kinase domain possesses tyrosine kinase activity. It phosphorylates downstream targets including STAT proteins, PIAS proteins, and the receptor itself.

Mutations and Polymorphisms

V617F (valine to phenylalanine at position 617): The most common mutation, found in ~60% of myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, primary myelofibrosis). This mutation disrupts JH2 domain autoinhibition, causing constitutive JAK2 activation.
Other mutations: L579R, K539L, R683G, and others have been identified in myeloproliferative disorders and solid tumors.

JAK-STAT Signaling Pathway

Canonical Signaling Cascade

Cytokine Binding: Ligand (e.g., IL-6, IFN-α) binds to its cognate receptor, inducing receptor dimerization.

JAK2 Activation: Associated JAK2 kinases undergo trans-autophosphorylation and activation.

Receptor Phosphorylation: Active JAK2 phosphorylates tyrosine residues on the cytokine receptor cytoplasmic domain.

STAT Recruitment: STAT proteins (STAT1, STAT3, STAT5) bind to phosphorylated receptor motifs via their SH2 domains.

STAT Phosphorylation: JAK2 phosphorylates critical tyrosine residues on STAT proteins.

STAT Dimerization: Phosphorylated STATs form parallel dimers.

Nuclear Translocation: STAT dimers translocate to the nucleus.

Gene Transcription: STAT dimers bind to DNA response elements and activate transcription of target genes.

Non-Canonical Pathways

Beyond STAT proteins, JAK2 activates: [@mud2016]

PI3K/AKT Pathway: Through receptor phosphorylation of PI3K docking sites
MAPK/ERK Pathway: Through Ras/Raf/MEK cascade activation
PLC-γ Pathway: Leading to calcium signaling

JAK2 in Neurodegenerative Diseases

Alzheimer's Disease (AD)

JAK2 signaling is significantly upregulated in AD brain and contributes to disease pathogenesis: [@chiba2012]

Neuroinflammation: [Aβ](/proteins/amyloid-beta) oligomers and fibrils activate astrocytes and microglia, triggering JAK2/STAT3 activation. This leads to production of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), creating a chronic inflammatory environment.
Microglial Activation: JAK2/STAT3 mediates microglial activation and phagocytosis. While beneficial for Aβ clearance, chronic activation leads to neurotoxicity.
[Tau](/proteins/tau) Pathology: JAK2/STAT3 activation can influence [tau](/proteins/tau) phosphorylation through effects on [GSK-3β](/entities/gsk3-beta) and [CDK5](/genes/cdk5).
Synaptic Dysfunction: JAK2 signaling affects synaptic plasticity and memory consolidation. STAT3 activation in neurons can alter excitatory/inhibitory balance.
Therapeutic Implications: JAK inhibitors (ruxolitinib, tofacitinib) reduce neuroinflammation and improve cognitive function in AD models.

Parkinson's Disease (PD)

Dopaminergic Neuron Stress: JAK2 is elevated in substantia nigra of PD patients. [α-Synuclein](/proteins/alpha-synuclein) aggregation can activate JAK2 signaling in neurons and glia.
Neuroinflammation: Microglial JAK2/STAT3 activation drives chronic neuroinflammation in the substantia nigra.
Mitochondrial Dysfunction: JAK2 signaling can intersect with mitochondrial quality control pathways.
Neuroprotection: JAK2 inhibitors protect dopaminergic neurons in experimental PD models.

Amyotrophic Lateral Sclerosis (ALS)

Astrocytic Dysfunction: Reactive astrocytes in ALS show enhanced JAK2/STAT3 signaling, contributing to non-cell-autonomous toxicity.
Microglial Activation: JAK2 mediates pro-inflammatory microglial responses.
Motor Neuron Vulnerability: JAK2 signaling can sensitize motor neurons to excitotoxic and oxidative stress.
Therapeutic Trials: JAK inhibitors are being investigated in ALS clinical trials.

Multiple Sclerosis (MS)

Autoimmune Pathogenesis: JAK2/STAT3 signaling is critical for T-cell differentiation and function in autoimmune demyelination.
CNS Inflammation: JAK inhibitors (tofacitinib, peginterferon) have shown efficacy in MS models and clinical trials.
Oligodendrocyte Function: JAK2 signaling affects oligodendrocyte progenitor cell differentiation and remyelination.

Expression in the Brain

JAK2 expression patterns in the central nervous system: [@saravia2020]

[Neurons](/entities/neurons): Moderate expression throughout [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), basal ganglia, and brainstem. Particularly high in pyramidal neurons.
[Astrocytes](/entities/astrocytes): High expression, further upregulated in reactive astrocytes.
[Microglia](/entities/microglia): High baseline expression, dramatically increased upon activation.
Oligodendrocytes: Lower expression in mature oligodendrocytes.

Cell-type specific functions: [@luo2020]

Neuronal JAK2: Regulates synaptic plasticity, neuroprotection
Astrocytic JAK2: Controls inflammatory cytokine production
Microglial JAK2: Mediates phagocytosis and inflammatory responses

Therapeutic Targeting

Approved JAK Inhibitors

Neurodegeneration Applications

Blood-Brain Barrier (BBB) Penetration: Many JAK inhibitors have limited BBB penetration. Newer compounds with improved CNS exposure are in development.
Dosing Considerations: CNS-directed therapy may require different dosing strategies.
Combination Approaches: JAK inhibitors combined with disease-modifying therapies may provide synergistic benefits.

Clinical Trials

Multiple clinical trials are evaluating JAK inhibitors in neurodegenerative diseases:

NCT03022799: Ruxolitinib in Alzheimer's disease (completed)
NCT04072614: Baricitinib in ALS (completed)
Various trials in MS with tofacitinib and peginterferon

Interaction Network

Overview

Background

The study of Jak2 Gene Janus Kinase 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Expression and Regulation

Tissue Distribution

JAK2 expression:

Hematopoietic cells: High expression in bone marrow
Brain: Neurons, astrocytes, microglia
Peripheral tissues: Liver, kidney, lung
Cell lines: Various leukemic cell lines

Transcriptional Control

Cytokine-induced: STAT5-mediated feedback
Epigenetic regulation: [DNA methylation](/entities/dna-methylation) patterns
Post-transcriptional: mRNA stability factors
Promoter elements: GAS, ISRE elements

Signaling Mechanisms

JAK-STAT Pathway

Core signaling cascade:

Ligand binding: Cytokine binds receptor

Receptor dimerization: Brings JAKs together

Transphosphorylation: JAKs activate each other

STAT recruitment: STAT proteins bind phosphotyrosines

Phosphorylation: JAKs phosphorylate STATs

Dimerization: STATs form active dimers

Nuclear translocation: Dimers enter nucleus

Gene transcription: Activate target genes

Downstream Effects

Immune genes: Cytokines, chemokines
Anti-apoptotic: Bcl-xL, Mcl-1
Cell proliferation: Cyclins, c-Myc
Differentiation: Lineage-specific genes

Neurobiology

Brain Expression

JAK2 in the CNS:

Neurons: Synaptic plasticity, survival
Astrocytes: Glial responses
Microglia: Inflammatory activation
[Blood-brain barrier](/entities/blood-brain-barrier): Endothelial regulation

Neuroinflammation

JAK2 in brain inflammation:

Cytokine signaling: IL-6, IFN-α, EPO
Microglial activation: Pro-inflammatory
Neuronal survival: Neuroprotective vs. harmful
Therapeutic potential: JAK inhibitors in CNS

Alzheimer's Disease

Aβ-induced activation: Amyloid stimulates JAK2
Tau phosphorylation: JAK2 can phosphorylate tau
Synaptic dysfunction: Alters synaptic plasticity
Neuroinflammation: Drives chronic inflammation

Parkinson's Disease

Dopaminergic neurons: Altered survival signaling
Neuroinflammation: Glial activation
Mitochondrial function: Links to PINK1/Parkin
Therapeutic target: JAK inhibitors

Animal Models

Knockout Studies

Jak2 knockout:

Embryonic lethal: E12.5-13.5 due to anemia
Conditional knockouts: Tissue-specific deletion
Brain-specific: Neuronal Jak2 deletion

Transgenic Models

V617F knockin: Myeloproliferative disease model
Neuronal expression: Neuroinflammation studies
Parkinson's models: MPTP treatment studies

Clinical Significance

Mutations

JAK2 mutations in disease:

V617F: Polycythemia vera (primary myelofibrosis)
Exon 12 mutations: Myeloproliferative neoplasms
Constitutional: Hereditary thrombocytosis

Myeloproliferative Neoplasms

Polycythemia vera: ~95% have JAK2 mutation
Essential thrombocythemia: ~50% JAK2 V617F
Primary myelofibrosis: ~60% JAK2 V617F

Therapeutic Targeting

JAK Inhibitors

CNS Challenges

Blood-brain barrier: Limited CNS penetration
Systemic effects: Immunosuppression
Peripheral vs CNS: Differing drug needs
Local delivery: Intrathecal approaches

Summary

JAK2 is a critical tyrosine kinase linking cytokine signaling to gene expression. In the brain, JAK2 participates in neuroinflammation and neuronal survival. JAK inhibitors are approved for myelofibrosis and autoimmune diseases, with potential applications in neurodegenerative disorders.

External Links

[JAK2 Gene - NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/3716)
[UniProt: O60674](https://www.uniprot.org/uniprot/O60674)
[OMIM: 147452](https://www.omim.org/entry/147452)
[Human Protein Atlas - JAK2](https://www.proteinatlas.org/ENSG00000096968-JAK2)

References

[Ben H, et al, (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30654698/)

[Liu J, et al, (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29578456/)

[Qin C, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32093412/)

[Nicolas S, et al, (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/22729177/)

[Mudò G, et al, (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27636841/)

[Chiba T, et al, (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/23202837/)

[Saravia J, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32205286/)

[Luo Y, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32017909/)

Liu X, et al, (2019) (2019)

[Zhong J, et al, (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27840247/)

Pathway Diagram

The following diagram shows the key molecular relationships involving JAK2 Gene - Janus Kinase 2 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

JAK2 Gene - Janus Kinase 2

JAK2 Gene - Janus Kinase 2

Overview

JAK2 Gene - Janus Kinase 2

Overview

Pathway Diagram

Introduction

Gene and Protein Structure

Domain Architecture

Mutations and Polymorphisms

JAK-STAT Signaling Pathway

Canonical Signaling Cascade

Non-Canonical Pathways

JAK2 in Neurodegenerative Diseases

Alzheimer's Disease (AD)

Parkinson's Disease (PD)

Amyotrophic Lateral Sclerosis (ALS)

Multiple Sclerosis (MS)

Expression in the Brain

Therapeutic Targeting

Approved JAK Inhibitors

Neurodegeneration Applications

Clinical Trials

Interaction Network

Overview

Background

Expression and Regulation

Tissue Distribution

Transcriptional Control

Signaling Mechanisms

JAK-STAT Pathway

Downstream Effects

Neurobiology

Brain Expression

Neuroinflammation

Alzheimer's Disease

Parkinson's Disease

Animal Models

Knockout Studies

Transgenic Models

Clinical Significance

Mutations

Myeloproliferative Neoplasms

Therapeutic Targeting

JAK Inhibitors

CNS Challenges

Summary

See Also

External Links

References

Pathway Diagram